Vimarsana
Biggest News Aggregation in the World

Page 7 - Research Protocol News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Research Protocol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Research Protocol Today - Breaking & Trending Today

Vikram Patel on TB among the vulnerable: When food is a vaccine - Vimarsana News

Vikram Patel on TB among the vulnerable: When food is a vaccine

As the landmark RATIONS study demonstrates, nutrition subsidies and addressing social determinants of diseases must become an essential part of healthcare

Furthering Education of Opioid Safety in Older Adults for Future Health Care Professionals - Vimarsana News

Furthering Education of Opioid Safety in Older Adults for Future Health Care Professionals

Nonpharmacologic and nonopioid treatments associated with improvements in pain and/or function that appear comparable to opioid treatments.

Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case–control study - Vimarsana News

Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case–control study

In a test-negative design case-control study, Dr. Thiago Cerqueira-Silva and colleagues, investigate the effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland.

Source: plos.org
Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case–control study - Vimarsana News

Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case–control study

In a test-negative design case-control study, Dr. Thiago Cerqueira-Silva and colleagues, investigate the effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland.

Source: plos.org
Unapproved stem cell therapies remains a top FDA enforcement priority | Hogan Lovells - Vimarsana News

Unapproved stem cell therapies remains a top FDA enforcement priority | Hogan Lovells

Speaking Tuesday at the Food and Drug Law Institute (FDLI) Annual Conference, Mark Raza, FDA Chief Counsel, discussed the investigations priorities for FDA’s Office of the Chief Counsel...